SCHEMBL13005681

SCHEMBL13005681

CC(C)Cc1cccc(CN(CCN(C)C)Cc2ccc(Br)cc2)c1

nearest known ligand 0.48

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CALM1 P0DP23 1/20 0.48
CAMKK2 Q96RR4 1/20 0.48
KDM4E B2RXH2 2/20 0.42
ALDH1A1 P00352 2/20 0.42
TAAR1 Q96RJ0 2/20 0.41
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
BCHE P06276 2/20 0.39
ACHE P22303 1/20 0.39
PYCR1 P32322 5/20 0.38
HTT P42858 2/20 0.36
TSHR P16473 2/20 0.36
L3MBTL1 Q9Y468 1/20 0.35
PTGES O14684 1/20 0.34
MEP1B Q16820 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13005702 0.90 TAAR1 (0.53) CALM1CAMKK2KDM4EALDH1A1TAAR1
SCHEMBL13005440 0.89 CALM1 (0.59) CALM1CAMKK2KDM4EALDH1A1TAAR1
SCHEMBL13005722 0.86 CALM1 (0.48) CALM1CAMKK2KDM4EALDH1A1TAAR1
SCHEMBL13005625 0.84 BCHE (0.47) CALM1CAMKK2TAAR1MEN1KMT2A
SCHEMBL14027648 0.84 TAAR1 (0.58) CALM1CAMKK2KDM4EALDH1A1TAAR1
SCHEMBL13005604 0.83 MEN1 (0.46) CALM1CAMKK2MEN1KMT2ABCHE
SCHEMBL13005607 0.83 BCHE (0.56) CALM1CAMKK2MEN1KMT2ABCHE
SCHEMBL13005692 0.82 TSHR (0.54) CALM1CAMKK2ALDH1A1TAAR1ACHE
SCHEMBL13005720 0.82 OPRK1 (0.49) CALM1CAMKK2MEN1KMT2A
SCHEMBL13005684 0.82 TAAR1 (0.53) CALM1CAMKK2ALDH1A1TAAR1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851637-B2 Compounds and methods for inhibiting the interaction of BCL proteins with binding partners INFINITY PHARMACEUTICALS, INC. (US) 2010-12-14 US disclosed
US-7851637-B2 Compounds and methods for inhibiting the interaction of BCL proteins with binding partners INFINITY PHARMACEUTICALS, INC. (US) 2010-12-14 US disclosed